TPC1 and C643 cells. Overall, both cancerous and N-thy cell lines express CYP27A1 and CYP2R1 in addition to CYP27B1, establishing the potential to metabolize D 3 to 1,25(OH) 2 D 3 . Additionally, vitamin D 3 , 25(OH)D 3 and 1,25(OH) 2 D 3 all had an antiproliferative effect on two thyroid cancer cell lines.
(VDRs) and that vitamin D, specifically 1,25(OH) 2 D 3 , has several potential therapeutic properties in patients suffering from these cancers. Mechanisms of 1,25(OH) 2 D 3 action in cancer include inhibition of proliferation associated with cell cycle arrest, induction of differentiation, reduction of both invasiveness and angiogenesis, and enhanced apoptosis [4] .
Formation of 1,25(OH) 2 D 3 involves several enzymatic steps. First, cholecalciferol is ingested via dietary sources or formed by the photoconversion of 7-dehydrocholesterol in the skin. It is then metabolized to 25(OH)D 3 in the liver by either the mitochondrial enzyme vitamin D 25-hydroxylase (CYP27A1) or the microsomal enzyme vitamin D 25-hydroxylase (CYP2R1) [5] [6] [7] . CYP27A1 appears to preferentially respond to D 3 , whereas CYP2R1 appears to respond equally to D 2 and D 3 [7] . Cheng et al. [6] reported a case of 25OHD 3 deficiency to have a mutation in the CYP2R1 gene on chromosome 11, suggesting that CYP2R1 may be the more biologically relevant vitamin D 25-hydroxylase in humans. 25(OH)D 3 is subsequently converted into 1,25(OH) 2 [3] .
It is already known that thyroid and thyroid cancer cells express VDRs and CYP27B1 [8, 9] . However, VDR expression is variable in distinct thyroid cancer cell lines (C643, BCPAP, Hth7, Hth74, K1, KAT18, SW1736 and TPC1), and the presence of VDR does not predict reduction in cell viability in response to treatment with calcitriol [1, 25(OH) 2 D 3 ] or a noncalcemic vitamin D analog [8] . One study showed that in vitro administration of calcitriol increased expression of the tumor suppressor protein p27 and decreased cell proliferation in the WRO follicular thyroid carcinoma cell line [10] . Increased expression of p27 also correlated with decreased metastatic spread [10] . The same group went on to demonstrate that in vivo calcitriol administration could restore p27 accumulation in thyroid carcinoma cells, an effect associated with appreciably enhanced cellular differentiation, reduction in tumor burden and prevention of metastatic growth [10] 
Materials and Methods

Cell Culture
Confirmed thyroid cancer cell lines [11] were obtained from Dr. Rebecca Schweppe, University of Colorado, with permission from the following researchers: BCPAP: female papillary thyroid cancer BRAF(V600E) mutation and KTC-1: male papillary thyroid cancer BRAF(V600E) mutation, from Dr. Junichi Kurebayashi; TPC1: p18 papillary thyroid cancer RET/PTC1 mutation, from Dr. Rebecca Schweppe; FTC133: p15 follicular thyroid cancer, from Dr. Electron Kebebew; Hth7: p90 anaplastic thyroid cancer BRAF WT and C643: p16 male anaplastic thyroid cancer HRAS (G13R) mutation, from Dr. Nils-Erik Heldin; N-thy: SV40-immortalized follicular cell line was purchased from the European Collection of Animal Cell Culture, Salisbury, UK, by Dr. Robert Anderson, Creighton University, Omaha, Nebr., USA, and we obtained these cells from him with permission. N-thy, BPCAP, TPC1, C643 and Hth7 cells were grown in RPMI /10% FBS + 0.1% gentamicin, and FTC133 and KTC-1 cells were grown in DMEM/ Ham's F12/10% FBS + 0.1% gentamicin. Cell lines were grown at 37 ° C with 5% CO 2 in a humidified environment. To avoid cross contamination, each cell line was cultured separately with a separate bottle of media in a sterile tissue culture hood.
STR Profiling
Because recent studies have shown that certain thyroid cancer cell lines have been of nonthyroid origin [11] , we performed STR (short tandem repeat) profiling to verify that the cell lines used in our study were of stated origin. DNA extraction was performed using Gentra Puregene Cell Kit, and DNA quantity was determined by measurement of absorbance at 260 and 280 nm using a Nanodrop spectrophotometer (Thermo Scientific) and by ethidium bromide staining on agarose gels. STR profiling was performed using the Applied Biosystems AmpF/STR Identifiler PCR Amplification kit (P/N 4322288) and results were cross referenced with cells proven to be unique thyroid cancer cell lines [11] .
Gene Expression CYP27A1, CYP2R1, CYP27B1, CYP24A1 and TATA binding protein (TBP) gene expression was determined in each cell line. Total RNA was extracted using the Purelink kit (Invitrogen), treated with RNase-free DNase, and then quantified using the Ribogreen assay (Invitrogen). The integrity and purity of the RNA was verified by visualization of rRNA on agarose gels. Equal amounts of RNA (2 g) were converted to cDNA using TaqMan High Capacity Reverse Transcriptase (Applied Biosystems), in a total reaction volume of 20 l. For real-time PCR analysis, the cDNA was diluted in an equal volume of nuclease-free water, and 1 l of the diluted cDNA was amplified using TaqMan Master Mix and predetermined TaqMan Gene Expression Assay primer and probe sets (Applied Biosystems), in a reaction volume of 50 l, in triplicate wells. These intron-spanning primers have been validated by the manufacturer to possess amplification efficiencies of 100 8 10% under the assay conditions. The real-time PCR reaction was performed using an ABI 7300 instrument. The gene expression assays used included CYP24A1 (assay Hs00167999_ m1, exon boundary 7-8 and amplicon length 123), CYP27A1 (assay Hs01017992_g1, exon boundary 8-9 and amplicon length 68), CYP2R1 (assay Hs01379776_m1, exon boundary 4-5 and amplicon length 79), CYP27B1 (assay Hs00168017_m1, exon boundary 8-9 and amplicon length 60) and TBP (assay Hs99999910_m1, exon boundary 6-6, amplicon length 127). The expression level of TBP within each cell line did not change with treatment. The CYP24A1, CYP2R1, CYP27A1 and CYP27B1 levels were normalized to that of TBP within each cell line, and relative gene expression was determined using the relative C T method.
Vitamin D Treatment
Experiments were performed in triplicate wells per condition and repeated three times (two times for CYP2R1). 
DNA Synthesis Assay
Cell proliferation was assessed by measurement of thymidine incorporation into DNA as described [15] . Briefly, cells were plated into triplicate wells of 24-well plates at 10 4 cells per well in growth medium containing serum. After 24 h, the medium was changed to growth medium containing D 3 , 25(OH)D 3 , 1,25(OH) 2 D 3 or ethanol, and cells were incubated for 72 h. The medium was again changed to growth medium containing D 3 , 1,25(OH) 2 D 3 or ethanol, and cells were incubated for 8 h. For the last 4 h of incubation, 0.1 Ci/ml [methyl-3 H]-thymidine (PerkinElmer) was added to the medium. After washing, DNA was precipitated with ice-cold 10% trichloroacetic acid, then solubilized in 0.1 N NaOH/0.1% sodium dodecyl sulfate. The extracted DNA was mixed with scintillation fluid (Optima Gold XR, Perkin-Elmer) and counted in a liquid scintillation counter.
Statistical Analysis
The design of the study includes 3 experimental factors: 'sample' with 7 levels, 'treatment' with 3 levels and 'detector' with 5 levels for a total of 105 factor combinations. Three replications for each combination of factors were made [63 observations for the 4 levels of detector (7 ! 3 ! 3) with extra replications for CYP2R1 giving this level 126 observations], providing a total sample size of n = 378 observations. Because of the extreme skewness of the data (all positive values), a log transformation was first applied. A three-way factorial ANOVA with unique residual variances for each level of sample was applied to these log-transformed data. The three-way interaction was determined to be significant (p ! 0.001). The objective of the study was to test the equality of the differences in least square means of the transformed data from 4 levels of detector (CYP27A1, CYP2R1, CYP27B1 and CYP24A1) with the reference level as TBP. Because both types of vitamin D (treatment) were dissolved in ethanol, the effect ethanol had on mRNA expression was removed during analysis after treatment with both D 3 and 1,25(OH) 2 D 3 to appropriately measure the effect that vitamin D treatment had on CYP27A1, CYP2R1, CYP27B1 and CYP24A1 mRNA expression. These differences across six levels of sample (BCPAP, KTC, TPC1, FTC133, C643 and Hth7) were then compared to the same differences computed for N-thy. Since multiple comparisons in factor levels were made, adjusted confidence intervals of these differences of differences were computed. Contrasts with corresponding adjusted p values ! 0.05 indicate a significant difference exists. The data were analyzed with PROC GLIMMIX [SAS STAT software for Windows, Version 9.2 (2008), Cary, N.C., USA]. For cell proliferation studies, curve-fitting and ANOVA analysis was performed using GraphPad Prism5 (GraphPad, LaJolla, Calif., USA).
Results
Baseline Levels of CYP27A1, CYP2R1, CYP27B1 and CYP24A1
We detected gene expression of both CYP27A1 and CYP2R1 in N-thy cells as well as in six distinct thyroid cancer cell lines ( fig. 1 ). Gene expression of CYP27A1 was variable amongst different thyroid cancer cell types. mRNA levels of CYP27A1 were significantly higher in BCPAP papillary and C643 anaplastic cells compared to N-thy (1.44 and 3.63, respectively, vs. 1.00, p ! 0.05), whereas mRNA levels of CYP27A1 in TPC1 papillary, FTC133 follicular and Hth7 anaplastic were significantly lower (0.12, 0.05 and 0.16, respectively, vs. 1.00, p ! 0.05). Levels were not statistically different in KTC-1 papillary cells compared to N-thy. In contrast, only mRNA levels of CYP2R1 in Hth7 cells were significantly higher than in N-thy (3.67 vs. 1.00, p ! 0.05). CYP27B1 mRNA expression was significantly higher in TPC1 papillary, BCPAP papillary, FTC133 follicular and Hth7 anaplastic cells when compared to N-thy cells 
Discussion
Even though CYP27A1 and CYP2R1 are most well known for their activity in the liver, we report the presence of CYP27A1 and CYP2R1 in the SV40 immortalized follicular cell line and six distinct thyroid cancer cell lines. It is already known that thyroid cells have VDRs and CYP27B1 and CYP24A1 gene expression [8] . Additionally, Sharma et al. [8, 16] The regulation of these enzymes is poorly understood and it is unknown if they are directly regulated by vitamin D 3 or 1,25(OH) 2 D 3 [5] . Additionally, the regulation of CYP27A1 or CYP2R1 may not be critical in determining the cell's ability to generate active vitamin D. Given the lack of gene expression response of either enzyme after treatment with D 3 and 1,25(OH) 2 D 3 , it will be important to measure active enzyme and protein expression of 25OHD 3 and 1,25(OH) 2 D 3 before and after treatment with D 3 both in vitro and in vivo to evaluate CYP27A1 and CYP2R1's true activity, especially since CYP2R1 has been reported to be the more biologically active enzyme in humans [6] .
When evaluating CYP27B1, none of the cell lines had a differential response in gene expression after treatment with D 3 , which may not be wholly unexpected since CYP27B1 is regulated through negative feedback by 1,25(OH) 2 D 3 in the kidney; however, regulation of these genes in extra-renal sites is poorly understood [5] . It may also indicate that there was not significant 1,25(OH) 2 D 3 production after treatment with D 3 since the expected result would be a decrease in the CYP27B1 gene expression. However, there was also no differential response in CYP27B1 gene expression when treated with 1,25(OH) 2 D 3 , suggesting it may not be regulated by negative feedback in the thyroid.
Baseline CYP24A1 gene expression varied in different cell types, but was consistently lower in all cancer cell lines compared with immortalized follicular thyroid cells. The lowest baseline CYP24A1 expression was in the TPC1 cells, followed by the C643 cells as the next lowest. After treatment with 1,25(OH) 2 D 3 , however, the cells lines with the lowest baseline values of CYP24A1 had the greatest increase in CYP24A1 mRNA. It is known that CYP24A1 gene expression is directly regulated by 1,25(OH) 2 D 3 , so it is logical that expression would increase with treatment with 1,25(OH) 2 D 3 and potentially D 3 (if there was adequate conversion to 25OHD 3 ). CYP24A1 gene expression is also regulated in response to activation of the VDR [3] and can be variable depending on whether the cells are relatively sensitive or resistant to vitamin D [8] . TPC1 papillary thyroid cancer cells had nearly undetectable baseline levels of CYP24A1, but Clinically, toxic levels of circulating 25(OH)D 3 are reported at 150 ng/ml (375 n M ). In this study, the concentrations that resulted in a reduction in cell proliferation are in that range (10-1,000 n M ). Hence, using vitamin D 3 or 25(OH)D 3 to achieve these circulating levels may not be clinically applicable. We saw equivalent inhibition of proliferation at approximately 10 M (10 -5 M ) for D 3 and 25(OH)D 3 , suggesting these effects cannot be explained by binding kinetics alone. It is not clear whether the effects on proliferation are from direct binding of the VDR or by conversion of inactive forms to active forms of vitamin D prior to binding, or a combination of the two. Chen et al. [17] showed that vitamin D 3 at high concentration can directly interact with isolated VDR. In their study, the relative effectiveness of 1,25(OH) 2 D 3 and D 3 on cell proliferation in keratinocytes was compared to direct binding to VDR. They found that D 3 inhibited proliferation at 10 n M to 1 M , while binding to VDR did not occur until 10 M . 10 M is where we see effects of D 3 in thyroid cells. This would argue that our effects could in fact be due to direct binding to D 3 . It is important to note, however, that these experiments were conducted over a limited time period (72 h). It is possible that, with longterm continuous treatment, D 3 may inhibit thyroid tumor growth in vivo.
Currently, there is no clear clinical association between serum 25(OH)D 3 levels and thyroid cancer [18] . Various forms of 1,25(OH) 2 D 3 have been used in clinical trials to treat different types of cancers, including prostate, colon and breast cancer [3] , producing variable results. One potential explanation for the variability is there are different relative amounts of CYP24A1 within specific cancers and that cancers containing higher levels of CYP24A1 will not benefit from 1,25(OH) 2 D 3 therapy. Several mechanisms exist to regulate the level of CYP24A1, one of which is post-transcriptional modification by micro RNA (miRNA). Low levels of miRNA125b result in higher levels of CYP24A1 [19] . Interestingly, significantly lower levels of miRNA125b have been found in anaplastic thyroid cancer compared to normal thyroid tissue [20] . It is plausible that the role vitamin D plays in cancer is not only related to baseline vitamin D, CYP27A1, CYP2R1, CYP27B1 and CYP24A1 levels, but also to baseline and stimulated CYP24A1 mRNA activity, an area of research that needs to be investigated more thoroughly. Variable CYP24A1 activity amongst different thyroid cancer cell lines would have implications on whether or not 1,25(OH) 2 D 3 therapy would be beneficial.
Not all the thyroid cancer cells had increased expression of CYP24A1 when compared to the N-thy cells. At this time, we do not have enough data to evaluate whether these differences can be due to differences in thyroid cancer cell types (i.e. papillary vs. follicular vs. anaplastic) alone, since the response within each histologic cell type was not similar. The largest response was in the TPC1 papillary and C643 anaplastic. These are very different histologically and clinically behave very differently, with papillary behaving much less aggressively than anaplastic. Consistent with their aggressiveness, TPC1 was also more sensitive to 1,25(OH)2D 3 than C643. Interestingly, they were approximately equal in their response to D 3 and 25(OH)D 3 . One possible explanation may be due to differences in genetic mutations (i.e. BRAF vs. RET vs. HRAS), given these were all distinct cell lines with different mutations. Anaplastic cell lines also had different mutations of origin. Hth7 cells have a known BRAF mutation, whereas C643 has an HRAS (G13R) mutation. Other potential explanations for differing response to vitamin D therapy could be the presence of VDR polymorphisms.
Conclusions
We report the presence of CYP27A1 and CYP2R1 mRNA expression in both cancerous and SV40 immortalized follicular cell lines, suggesting that thyroid cells may have the ability to locally produce active vitamin D from its precursor D 3 
